The ABPI has appointed David Watson as the Association’s new Head of Commercial. David will report to ABPI Executive Director, Commercial UK, Alison Clough.
David’s work will focus on implementing the 2014 PPRS on behalf of industry and he will work closely with the Department of Health and scheme members. Previously David worked with global marketing experts Cello Consulting, and prior to that with Pfizer, where he held a number of roles in marketing, sales and commercial operations.
Commenting on his appointment David said:
“I am delighted to join the ABPI at what is an important time for the industry following the recent PPRS agreement. I look forward to working with colleagues both within the ABPI and externally to ensure the full implementation of the new PPRS agreement and ensure that patients have access to the latest innovative medicines.”
Welcoming David’s appointment Alison Clough said:
“I am looking forward to working with David on the implementation of the new PPRS agreement. It is vital that the PPRS is fully implemented and that the pharmaceutical industry continues to work with the Department of Health and NHS England, using the platform that the new PPRS gives us, to help address the poor usage in the UK of innovative medicines for the benefit of patients. David is a very welcome addition to the team”.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: [email protected]